Clinical trials: Docetaxel
Recurrent Non-Small Cell Lung Carcinoma, Stage IV Non-Small Cell Lung Cancer
Maintenance Chemotherapy With or Without Local Consolidative Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer
This randomized phase II/III trial studies how well giving maintenance chemotherapy with or without local consolidation therapy works in treating patients with stage IV non-small cell lung cancer.
- Trial name
- NCT03137771
- Testing
- 3-Dimensional Conformal Radiation Therapy (3D-CRT), Docetaxel, Gemcitabine
- Where
- 301 sites in United States, Canada and 2 more
- Volunteers
- 218 people
- Sponsor
- NRG Oncology
Breast Cancer
Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
The purpose of this study is to find out if the combination of docetaxel and capecitabine can shrink the size of breast tumors and preserve the breast.
- Trial name
- NCT00209092
- Testing
- Docetaxel, Capecitabine
- Where
- 19 sites in United States
- Volunteers
- 51 people
- Sponsor
- Emory University
Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8
Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients With Stage II-III Laryngeal Cancer
This phase II trial studies how well cisplatin, docetaxel, and pembrolizumab work in treating patients with stage II-III laryngeal cancer.
- Conditions
- Laryngeal Squamous Cell Carcinoma, Stage II Laryngeal Cancer AJCC v8, Stage III Laryngeal Cancer AJCC v8
- Trial name
- NCT04030455
- Testing
- Carboplatin, Cisplatin, Docetaxel
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- M.D. Anderson Cancer Center
Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma
Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma
This randomized phase III trial is studying gemcitabine hydrochloride, docetaxel, and bevacizumab to see how well they work compared with gemcitabine hydrochloride, docetaxel, and a placebo in treating patients with advanced or…
- Conditions
- Recurrent Uterine Corpus Sarcoma, Stage IIIA Uterine Sarcoma, Stage IIIB Uterine Sarcoma, Stage IIIC Uterine Sarcoma
- Trial name
- NCT01012297
- Testing
- Bevacizumab, Docetaxel, Filgrastim
- Where
- 201 sites in United States
- Volunteers
- 107 people
- Sponsor
- National Cancer Institute (NCI)
Neoplasms
A Phase I Dose Escalation Trial of Afatinib Plus Gemcitabine or Plus Docetaxel
To establish the maximum tolerated dose (MTD) of oral afatinib (BIBW2992) given in combination with gemcitabine or docetaxel in patients with relapsed or refractory tumors. To assess the safety of the combination.
- Trial name
- NCT01251653
- Testing
- Afatinib, docetaxel, gemcitabine
- Where
- 3 sites in France
- Volunteers
- 94 people
- Sponsor
- Boehringer Ingelheim
Breast Cancer
Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00665457
- Testing
- filgrastim, capecitabine, celecoxib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- University of Nebraska
Cancer
Docetaxel, Cetuximab and Cisplatin Followed by Radiation, Cetuximab and Cisplatin in Head and Neck Cancer
The purpose of this study is to determine if the addition of a unique targeted agent called Cetuximab (also known as "C225" and "Erbitux") can increase the effectiveness of standard treatment with chemotherapy and radiation.
- Trial name
- NCT00226239
- Testing
- Docetaxel, Cisplatin, Cetuximab
- Where
- United States
- Volunteers
- 39 people
- Sponsor
- University of Pittsburgh
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or…
- Trial name
- SAPPHIRE (NCT03906071)
- Testing
- Nivolumab, Sitravatinib, Docetaxel
- Where
- 261 sites in United States, Belgium and 10 more
- Volunteers
- 577 people
- Sponsor
- Mirati Therapeutics Inc.
Any Cancer, Breast Cancer
A Study of the Proper Dosage of Lovastatin and Docetaxel for Patients With Cancer
This purpose of this study is to evaluate the use of two medications, docetaxel and lovastatin to determine the highest dose of lovastatin and docetaxel that can be given safely as well as the safety of combining the two drugs…
- Trial name
- NCT00584012
- Testing
- Lovastatin, Docetaxel
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Susan L Roeder
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well docetaxel given together with cisplatin and pegfilgrastim followed by erlotinib hydrochloride works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT01557959
- Testing
- cisplatin, pegfilgrastim, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Locally Advanced or Metastatic Unresectable Urothelial Cancer
Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread
The primary objective of this study is to assess overall survival (OS) with sacituzumab govitecan-hziy in comparison with treatment of physician's choice (TPC) in participants with metastatic or locally advanced unresectable…
- Trial name
- TROPiCS-04 (NCT04527991)
- Testing
- Sacituzumab Govitecan-hziy, Paclitaxel, Docetaxel
- Where
- 234 sites in United States, Australia and 25 more
- Volunteers
- 711 people
- Sponsor
- Gilead Sciences
Breast Cancer
Doxorubicin HCI Liposome Injection Versus Weekly Docetaxel in Patients First Relapse Metastatic Breast Cancer
The efficacy of single agent liposomal doxorubicin as compared to single agent docetaxel will be evaluated as first line treatment in metastatic breast cancer patients, with subsequent crossover to the opposite arm at disease…
- Trial name
- NCT00193037
- Testing
- Liposomal Doxorubicin, Docetaxel
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- SCRI Development Innovations, LLC
Lung Cancer
Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
RATIONALE: Drugs used in chemotherapy, such as carboplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00280735
- Testing
- carboplatin, docetaxel
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Carcinoma, Non-Small-Cell Lung
Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)
The main purpose of this study was to demonstrate superiority with regard to overall survival of avelumab versus docetaxel in participants with programmed death ligand 1 (PD-L1) positive, non-small cell lung cancer (NSCLC) after…
- Trial name
- NCT02395172
- Testing
- Avelumab, Docetaxel
- Where
- 260 sites in United States, Argentina and 27 more
- Volunteers
- 792 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Neoplasm
A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)
This study will evaluate PF-05212384 (gedatolisib) PI3K/mTOR inhibitor)) in combination with either docetaxel, cisplatin or dacomitinib in select advanced solid tumors.
- Trial name
- NCT01920061
- Testing
- PF-05212384 (gedatolisib), Docetaxel, Cisplatin
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 110 people
- Sponsor
- Pfizer
Head and Neck Cancer
Docetaxel, Cisplatin, and Fluorouracil Followed By Cetuximab and Radiation Therapy in Treating Patients With Locally Advanced Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, and fluorouracil, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00721513
- Testing
- cetuximab, cisplatin, docetaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Breast Cancer
A Study of Pertuzumab in Combination With Herceptin in Patients With HER2 Positive Breast Cancer.
This 4 arm study will evaluate the efficacy and safety of 4 neoadjuvant treatment regimens in female patients with locally advanced, inflammatory or early stage HER2 positive breast cancer.
- Trial name
- NCT00545688
- Testing
- Herceptin, Docetaxel, Pertuzumab
- Where
- 77 sites in Australia, Austria and 16 more
- Volunteers
- 417 people
- Sponsor
- Hoffmann-La Roche
Breast Neoplasms
Randomized Study Evaluating Ixabepilone Plus Capecitabine or Docetaxel Plus Capecitabine in Metastatic Breast Cancer
The purpose of this study is to assess the effect of ixabepilone plus capecitabine or docetaxel plus capecitabine on shrinking or slowing the growth of metastatic breast cancer in women.
- Trial name
- IXTEND (NCT00546364)
- Testing
- Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2, Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2, Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
- Where
- 60 sites in United States
- Volunteers
- 62 people
- Sponsor
- R-Pharm
Cancer
Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma
This study will aims to determine the maximum tolerated dose of CGC-11047 when used in individual combinations with gemcitabine, or docetaxel, or bevacizumab, or erlotinib or cisplatin or 5-flurouracil or sunitinib in one of 7…
- Trial name
- NCT00705874
- Testing
- CGC-11047 and gemcitabine, CGC-11047 and docetaxel, CGC-11047 and bevacizumab
- Where
- 12 sites in United States
- Volunteers
- 172 people
- Sponsor
- Progen Pharmaceuticals
Non Small Cell Lung Cancer
A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)
The purpose of this neoadjuvant study is to compare nivolumab plus chemotherapy and chemotherapy alone in terms of safety and effectiveness, and to describe nivolumab plus ipilimumab's safety and effectiveness in treating…
- Trial name
- CheckMate 816 (NCT02998528)
- Testing
- Nivolumab, Cisplatin, Vinorelbine
- Where
- 138 sites in United States, Argentina and 13 more
- Volunteers
- 505 people
- Sponsor
- Bristol-Myers Squibb